NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)
Clinical trial NCT05451654 · TERMINATED
Trial details
- NCT number
- NCT05451654
- Sponsor
- Medesis Pharma SA
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-04
- Primary completion
- 2022-10-04
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.